Delivery Order SPE2DB25D3201-SPE2DB25FNVFC
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $7,391.80 delivery order for Padcev 20 mg vials under a firm fixed-price contract with an ultimate completion date of August 11, 2025. This is a non-set-aside award, meaning it was competitively awarded without restrictions. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a $11,087.60 delivery order to AmerisourceBergen Drug Corp for Padcev 30 mg vials, with an ultimate completion date of August 8, 2025. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania. The delivery order was awarded on July 18, 2025, as part of AmerisourceBergen's broader engagement with the federal government for pharmaceutical supply. This delivery order falls under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a delivery order valued at $5,543.80 to AmerisourceBergen Drug Corp for the supply of PADCEV 30 mg vials. This contract is a firm fixed-price delivery order with no set-aside designation, issued competitively on July 21, 2025, and scheduled for completion by August 11, 2025. The products will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This award represents a child...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $27,719 on July 28, 2025, for the supply of Padcev 30 mg vials. This firm fixed-price delivery order, which is expected to be completed by August 18, 2025, was issued without a set-aside designation, indicating it was competitively awarded. The contract is performed at the awardee's Corporate Office location in Conshohocken, PA and is funded...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,695.90 contract is for the delivery of PADCEV 20 MG VIAL 1S medical supplies. The contract is non-set-aside, indicating open competition. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
- The Defense Logistics Agency awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide PADCEV 30 MG VIALS. This $20,823.75 contract has a completion date of January 23, 2024. Amerisourcebergen Drug Corp, which provides pharmaceuticals and medical supplies to government agencies including the Department of Defense, was the prime contractor for this award. No set-aside designation was used. The pharmaceutical products are to...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation. The $9,999.72 order is for the supply of PADCEV 30 mg vials, a pharmaceutical product, with a completion date of February 12, 2024. Amerisourcebergen Drug Corp has received numerous prior federal contract awards to provide pharmaceuticals, medical supplies, and...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, to supply PADCEV 30 MG Vials. The contract has a firm fixed price of $11,087.60 and a performance period ending on July 14, 2025. It is not designated as a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a for-profit global pharmaceutical sourcing and distribution company. The order is for PADCEV 20 MG VIALS, a specialty pharmaceutical product, with a completion date of March 14, 2024 and a potential value of $13,318.56. This delivery order is issued under an indefinite delivery contract (IDC) held by...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,046.40, is for the supply of PADCEV 30 MG VIALS, a pharmaceutical product. The contract has an ultimate completion date of May 5, 2025 and is a firm fixed-price, delivery order contract with no set-aside designation. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB25FNVFCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,087.70 to AmerisourceBergen Drug Corp for the supply of Padcev 20 mg vials. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 19, 2025, and carries no set-aside designation. The contract will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order under its existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated as SPE2DX, a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs. Padcev (enfortumab vedotin) is a specialized oncology therapeutic used primarily in the treatment of certain urinary tract cancers. This delivery order represents a routine procurement action within AmerisourceBergen's extensive federal contract portfolio, which demonstrates the company's consistent capability to supply pharmaceutical products ranging from specialty medications to vaccines and medical devices across multiple therapeutic domains. The company's federal contracting history reflects its role as a critical vendor for Defense Health Agency, U.S. Coast Guard, and broader military healthcare systems, supporting medical supply chain requirements both domestically and globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 7/29/25 |